FAM3A

Across TCGA pan-cancer cohorts, FAM3A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM3A data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM3A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM3A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where FAM3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.819	.007	24	view →
LSCC	DFS	Quartile	All	0.811	0.999	.009	8	view →
GBM	DFS	Median	All	0.168	0.529	.022	5	view →
PDAC	OS	Tertile	III,IV	0.383	1.000	.022	4	view →
LUAD	OS	Quartile	III,IV	1.000	0.618	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM3A–CCRCC (DFS)

Open the CCRCC breakdown →